Scientific Program – ART/IVF/Infertility

Friday, November 13 & Saturday, November 14, 2026

08:30
08:40
08:50

Debate: Any place for AI in ovulation induction

Yes:
No: 
Discussion

Preimplantation genetic testing for aneuploidy versus morphological selection: Results of a pilot RCT

Discussion

New developments in the use of AI for ovarian stimulation
Vasiliki A. Moragianni, USA

Discussion

The surprising results of the optimal follicular size before trigger: What AI reveals?
Simon Hanassab, UK

Discussion

Modifying the pool of recruitable antral follicles…. Really? How?

Discussion

11:10
11:20
11:30

Debate: Stem cells or surgery for Asherman syndrome?

Operation, even in extreme cases – what are the limits? Ettore Cicinelli, Italy
Stem cells for endometrial regeneration: Xavier Santamaria,Spain
Discussion

Industry supported session – Hall A
Industry supported session – Hall B

Ethnic disparities in IVF success, implications to treatment personalization
Simon Hanassab, UK

14:45
14:55
15:05

Debate: What is the origin of implantation failure?

Euploidy is crucial and is age-dependent: Paul Pirtea, France
Euploidy is not enough for implantation:
Discussion

Immunological factor – Endometrial profiling and LBR (RCT)

Modern IVF settings: is the cost rising while the chances are falling?
Norbert Gleicher, USA

Low resources setting, high IVF results
Willem Ombelet, Belgium

After how many IVF failures should we adopt add-ons?
Edgardo Somigliana, Italy

17:15
17:25
17:35

Debate: Intramural fibroids should be enucleated before IVF

Yes:
No:
Discussion

Hysteroscopic management of submucous fibroids: Techniques and limitations

Multiple uterine fibroids: How to select the appropriate operative procedure?
Angelos Daniilidis, Greece

Name change: Patients perspective

Name change: The health care providers perspective
Terhi Piltonen, Finland

Name Change: Dissemination of the new name
Joop Laven, Netherlands

Do we agree that all cases with Mosaicism can be transferred and should not be reported

10:50
11:00
11:10

Debate: Claims of lower miscarriage rate and speed up of the time to pregnancy

Pro: This justifies the cost and utilization of PGT-A!
Con: Only if we don’t trust the RCTs showing no effect of PGT-A?
Discussion

Invasive vs Noninvasive PGT -A: From cell DNA to cell – free DNA
Dimitris Loutradis, Greece

Why we decided to sue the PGT-A

Epigenetics and reprogramming

Questions to the panel

Embryology

• Sperm separation and selection techniques: Do any really improve embryo quality and outcomes?
• Should time-lapse imaging be implemented for all ART cycles?
• Should genetic carrier screening be proposed systematically before ART?
• Is non-invasive PGT-A still a promising approach?
• Does the number of laser pulses impact embryo biopsy

Clinical aspects of IVF

• Rescue IVM: Is it clinically relevant
• Could artificial intelligence take over aspects of clinical management in ART?
• Does recurrent implantation failure still exist as a distinct entity?
• How can we decrease the cost of IVF, is natural IVF still useful in current practice?
• Is preeclampsia truly more frequent after artificial embryo transfer cycles?
• Mild ovarian stimulation for patients with diminished ovarian reserve: myth or reality?

Personalization of ovarian stimulation, do we need to base it on age and Markers of ORT
Frank Broekmans, Netherlands

15:30
15:40
15:50

Debate: How important is the choice of gonadotropins and monitoring during stimulation?

It is important: Evangelos Makrakis, Greece
No better results were proven:
Discussion

16:00
16:10
16:20

Higher doses will increase oocyte yield Frank Broekmans, Netherlands
Mild stimulation is the right way Paul Pirtea, France
Discussion